Suppr超能文献

相似文献

1
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Cancer Discov. 2014 Mar;4(3):334-47. doi: 10.1158/2159-8290.CD-13-0611. Epub 2014 Jan 16.
3
Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Mol Cancer Ther. 2015 Apr;14(4):1014-23. doi: 10.1158/1535-7163.MCT-14-0669. Epub 2015 Feb 11.
4
Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.
6
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8.
9
PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.

引用本文的文献

2
Unlocking the power of probiotics, postbiotics: targeting apoptosis for the treatment and prevention of digestive diseases.
Front Nutr. 2025 Mar 31;12:1570268. doi: 10.3389/fnut.2025.1570268. eCollection 2025.
4
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance.
Nat Cancer. 2024 Aug;5(8):1250-1266. doi: 10.1038/s43018-024-00781-6. Epub 2024 Jul 11.
5
7
Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Oncogene. 2024 Mar;43(13):921-930. doi: 10.1038/s41388-024-02958-w. Epub 2024 Feb 9.
8
Oxygen and Iron Availability Shapes Metabolic Adaptations of Cancer Cells.
World J Oncol. 2024 Feb;15(1):28-37. doi: 10.14740/wjon1739. Epub 2024 Jan 10.

本文引用的文献

1
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Mol Cancer Ther. 2013 Nov;12(11):2319-30. doi: 10.1158/1535-7163.MCT-12-0993-T. Epub 2013 Oct 29.
2
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. doi: 10.6004/jnccn.2013.0086.
3
Development of PI3K inhibitors: lessons learned from early clinical trials.
Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Epub 2013 Feb 12.
5
Comprehensive molecular portraits of human breast tumours.
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
6
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.
Cancer Cell. 2012 Feb 14;21(2):227-39. doi: 10.1016/j.ccr.2011.12.024.
7
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Cancer Discov. 2011 Aug;1(3):248-59. doi: 10.1158/2159-8290.CD-11-0085. Epub 2011 Jun 17.
8
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.
9
Phosphoinositide 3-kinase regulates plasma membrane targeting of the Ras-specific exchange factor RasGRP1.
J Biol Chem. 2011 Apr 8;286(14):12712-23. doi: 10.1074/jbc.M110.189605. Epub 2011 Feb 1.
10
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验